Eli Lilly's Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) in early-stage RET fusion-positive NSCLC met its primary endpoint, a favorable clinical readout for the oncology franchise. The result supports the drug's potential in the adjuvant setting and strengthens Lilly's oncology pipeline. The news is positive for the stock but likely to be a modest individual-name move rather than a sector-wide event.
Eli Lilly's Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) in early-stage RET fusion-positive NSCLC met its primary endpoint, a favorable clinical readout for the oncology franchise. The result supports the drug's potential in the adjuvant setting and strengthens Lilly's oncology pipeline. The news is positive for the stock but likely to be a modest individual-name move rather than a sector-wide event.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
